MB-101 is under clinical development by Mustang Bio and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect MB-101’s likelihood of approval (LoA) and phase transition for Ependymoma took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their MB-101 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
MB-101 is under development for the treatment of recurrent or refractory glioblastoma multiforme. It is administered through intratumoral infusion or intracavitary or intraventricular catheter, intracerebroventricular (ICV) delivery. The therapy comprises of central memory enriched T cells lentivirally transduced to express an IL13R-apha2-specific, hinge-optimized, 41BB-costimulatory chimeric receptor and a truncated CD19. It acts by targeting interleukin 13 receptor alpha-2 (IL13R alpha 2).
Mustang Bio overview
Mustang Bio is an US based developer of cell and gene therapies for the treatment of AML and brain cancer.
Quick View MB-101 LOA Data
|Highest Development Stage|